Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors

dc.contributor.authorChambers, Andrea M.
dc.contributor.authorLupo, Kyle B.
dc.contributor.authorWang, Jiao
dc.contributor.authorCao, Jingming
dc.contributor.authorUtturkar, Sagar
dc.contributor.authorLanman, Nadia
dc.contributor.authorBernal-Crespo, Victor
dc.contributor.authorJalal, Shadia
dc.contributor.authorPine, Sharon R.
dc.contributor.authorTorregrosa-Allen, Sandra
dc.contributor.authorElzey, Bennett D.
dc.contributor.authorMatosevic, Sandro
dc.contributor.departmentMedicine, School of Medicine
dc.date.accessioned2023-08-09T16:39:11Z
dc.date.available2023-08-09T16:39:11Z
dc.date.issued2022-07-11
dc.description.abstractImmunometabolic reprogramming due to adenosine produced by CD73 (encoded by the 5'-ectonucleotidase gene NT5E) is a recognized immunosuppressive mechanism contributing to immune evasion in solid tumors. Adenosine is not only known to contribute to tumor progression, but it has specific roles in driving dysfunction of immune cells, including natural killer (NK) cells. Here, we engineered human NK cells to directly target the CD73-adenosine axis by blocking the enzymatic activity of CD73. In doing so, the engineered NK cells not only impaired adenosinergic metabolism driven by the hypoxic uptake of ATP by cancer cells in a model of non-small-cell lung cancer, but also mediated killing of tumor cells due to the specific recognition of overexpressed CD73. This resulted in a 'single agent' immunotherapy that combines antibody specificity, blockade of purinergic signaling, and killing of targets mediated by NK cells. We also showed that CD73-targeted NK cells are potent in vivo and result in tumor arrest, while promoting NK cell infiltration into CD73+ tumors and enhancing intratumoral activation.
dc.eprint.versionFinal published version
dc.identifier.citationChambers AM, Lupo KB, Wang J, et al. Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors. Elife. 2022;11:e73699. Published 2022 Jul 11. doi:10.7554/eLife.73699
dc.identifier.urihttps://hdl.handle.net/1805/34817
dc.language.isoen_US
dc.publishereLife Sciences
dc.relation.isversionof10.7554/eLife.73699
dc.relation.journaleLife
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourcePMC
dc.subjectAdenosine
dc.subjectImmunology
dc.subjectImmunometabolism
dc.subjectImmunotherapy
dc.subjectInflammation
dc.subjectNatural killer cells
dc.titleEngineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
elife-73699.pdf
Size:
3.81 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: